

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
 - TEXT CUT OFF AT TOP, BOTTOM OR SIDES
 - FADED TEXT
 - ILLEGIBLE TEXT
 - SKEWED/SLANTED IMAGES
 - COLORED PHOTOS
 - BLACK OR VERY BLACK AND WHITE DARK PHOTOS
 - GRAY SCALE DOCUMENTS
-

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problems Mailbox.**

THIS PAGE BLANK (USPTO)

MORRISON & FOERSTER LLP

Attorneys at Law
3811 Valley Centre Drive
Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-5100
Facsimile: (858) 720-5125

To:

NAME:	FACSIMILE:	TELEPHONE:
Examiner Dong Jiang USPTO	(703) 746-5063	(703) 305-1345

FROM: David L. Devernoe

DATE: December 16, 2003

Number of pages with cover page:	15
----------------------------------	----

Preparer of this slip has confirmed that facsimile number given is correct: 7775/dld3

CAUTION - CONFIDENTIAL

This facsimile contains confidential information which may also be privileged. Unless you are the addressee (or authorized to receive for the addressee), you may not copy, use, or distribute it. If you have received it in error, please advise Morrison & Foerster LLP immediately by telephone or facsimile and return it promptly by mail.

Comments:

Proposed Interview agenda (including proposed claim amendments and one reference) for discussion on December 18, 2003 1:30pm (EST)

U.S. Application No. 09/636,530

PLEASE DO NOT ENTER INTO RECORD

FOR DISCUSSION PURPOSES ONLY

Privileged and Confidential

FOR DISCUSSION PURPOSES ONLY - DO NOT ENTER INTO RECORD

In re Patent Application of:
Thomas L. CANTOR

Application No.: 09/636,530

Filed: August 10, 2000

Art Unit: 1646

Examiner: Dong Jiang

For: PARATHYROID HORMONE ANTAGONISTS
OR MODULATORS AND USES THEREFOR

INTERVIEW AGENDA - 12/18/03

Issue 1 (New Matter): Whether claim 14, directed to a PTH antagonist composition with an N-terminus starting at any position spanning from 8 through 34 of SEQ ID NO: 1 is supported in the specification.

Our position: (1) Amended claim 14 is supported at, e.g., pg 1, lns 8-12; pg 4, lns 4-13; pg 5, lns 23-26; and sequence listing; (2) the claimed antagonist falls within the original described and claimed range; (3) multiple examples (e.g., PTH₉₋₈₄, PTH₂₈₋₈₄ and PTH₃₄₋₈₄) are provided within the range (see, e.g., pg 1, lns 10-11; pg 4, lns 5-6; and pg 5, lns 23-26); and (4) legal support for our position can be found, e.g., in *In re Wertheim*, 191 USPQ 90 (CCPA 1976); *In re Driscoll*, 195 USPQ 434, 437-38 (CCPA 1977); MPEP § 2163.05 (range limitations); and *Moba, B.V. v. Diamond Automation, Inc.*, 325 F.3d 1306, 1321 (Fed. Cir. 2003) (acknowledging the test for sufficiency of support in an application is whether an artisan would recognize possession as set out in the disclosure).

Issue 2 (Anticipation): (1) Whether *Takasu* anticipates claims 14 and 16; and (2) whether *Fukuda* anticipates claims 22-25 and 30-33.

Our positions: *Takasu* - *Takasu's* mutein consists of hPTH (35-84); but the claims require an N-terminus spanning between positions 8 and 34, and a C-terminus at 84. Thus, all limitations are not present in *Takasu*. Anticip. b)

Fukuda - (1) In contrast to the present claims, *Fukuda's* muteins stimulate adenylate cyclase activity (ACA), as evidenced by the measured mutein-stimulated ACA-linked cAMP levels (see *Fukuda* "Experimental Example" page 23; and *Shigeno et al.* (included herewith and cited in the *Fukuda* Example)); and (2) no indication that any of *Fukuda's* thousands of muteins have "antagonistic" activity in accordance with the current claims.

Issue 3 (Obviousness): Whether claims 26-29 and 34-38 are rendered obvious by *Fukuda* and *Kanmera*.

Our position: *Fukuda* (see above). *Kanmera* - With regard to the adenylate cyclase activity of *Fukuda's* and *Kanmera's* muteins, even when taken together, the references do not teach the present claim limitations (see above and *Kanmera* at pages 8-10). Further, *Kanmera* appears to teach PTHrP substituted derivatives and teaches away from the use of: (1) truncated PTH or PTHrP fragments as they lack the desired "activity levels"; and (2) substituted PTH or PTHrP fragments as they lack predictable activity. See, e.g., pg 2, lns 47-58. Each of *Fukuda's* muteins tested for "antagonistic" activity were substituted, thus no reasonable expectation of success seems present if combined with *Kanmera*.

Privileged and Confidential
FOR DISCUSSION PURPOSES ONLY - DO NOT ENTER INTO RECORD

Proposed Claim Amendments

Claims 1-13 (Cancelled)

14. **(Proposed Amendment - For Discussion Only)** A pharmaceutical parathyroid hormone (PTH) antagonist composition, wherein the PTH antagonist composition comprises a peptide exhibiting PTH antagonist activity, together with a pharmaceutical carrier or excipient, wherein the PTH antagonist comprises a contiguous portion of human PTH having an amino acid sequence set forth in SEQ ID NO:1 (PTH₁₋₈₄), ~~and that~~ has the following characteristics:

- a) the N-terminal amino acid residue of the PTH antagonist starts at any position spanning from position 8 through position 34 of SEQ ID NO:1 (PTH₁₋₈₄); and
- b) the C-terminal amino acid residue of the PTH antagonist ends at position 84 of SEQ ID NO:1 (PTH₁₋₈₄).

Claim 15 (Cancelled)

16. **(Previously amended)** The antagonist of claim 14, wherein the PTH antagonist is selected from the group consisting of SEQ ID NO:5 (PTH₂₈₋₈₄) and SEQ ID NO:3 (PTH₃₄₋₈₄).

Claims 17-21 (Cancelled)

22. **(Proposed Amendment - For Discussion Only)** A method for treating a patient having hyperparathyroidism comprising administering to a patient having hyperparathyroidism a PTH antagonist peptide exhibiting PTH antagonist activity, ~~which antagonist activity comprises decreasing the in vivo calcium ion concentration in the blood of the patient or countering hypercalcemia, wherein said PTH antagonist peptide avoids stimulating adenylate cyclase activity,~~ in a therapeutically effective, but non-toxic amount, wherein the PTH antagonist comprises a contiguous portion of human PTH having an amino acid sequence set forth in SEQ ID NO:1 (PTH₁₋₈₄), ~~and that~~ has the following characteristics:

- a) the N-terminal amino acid residue of the PTH antagonist starts at any position spanning from position 2 through position 34 of SEQ ID NO:1 (PTH₁₋₈₄); and
- b) the C-terminal amino acid residue of the PTH antagonist ends at position 84 of SEQ ID NO:1 (PTH₁₋₈₄).

23. **(Previously presented)** The method of claim 22, wherein the N-terminal amino acid residue of the PTH antagonist starts at any position spanning from position 3 through position 28 of SEQ ID NO:1 (PTH₁₋₈₄), and the C-terminal amino acid residue of the PTH antagonist ends at position 84 of SEQ ID NO:1 (PTH₁₋₈₄).

Privileged and Confidential
FOR DISCUSSION PURPOSES ONLY - DO NOT ENTER INTO RECORD

Proposed Claim Amendments

24. (Previously presented) The method of claim 22, wherein the PTH antagonist is selected from the group consisting of SEQ ID NO:2 (PTH₂₋₈₄), SEQ ID NO:4 (PTH₃₋₈₄), SEQ ID NO:5 (PTH₂₈₋₈₄), and SEQ ID NO:3 (PTH₃₄₋₈₄).

25. (Previously presented) The method of claim 22, wherein the PTH antagonist is administered together with a pharmaceutical carrier or excipient.

26. (Proposed Amendment - For Discussion Only) A method for treating a patient having renal osteodystrophy comprising administering to a patient having renal osteodystrophy a PTH antagonist peptide exhibiting PTH antagonist activity, ~~which antagonist activity comprises decreasing the *in vivo* calcium ion concentration in the blood of the patient or countering hypercalcemia,~~ wherein said PTH antagonist peptide avoids stimulating adenylate cyclase activity, in a therapeutically effective, but non-toxic amount, wherein the PTH antagonist comprises a contiguous portion of human PTH having an amino acid sequence set forth in SEQ ID NO:1 (PTH₁₋₈₄), ~~and that~~ has the following characteristics:

- a) the N-terminal amino acid residue of the PTH antagonist starts at any position spanning from position 2 through position 34 of SEQ ID NO:1 (PTH₁₋₈₄); and
- b) the C-terminal amino acid residue of the PTH antagonist ends at position 84 of SEQ ID NO:1 (PTH₁₋₈₄).

27. (Previously presented) The method of claim 26, wherein the N-terminal amino acid residue of the PTH antagonist starts at any position spanning from position 3 through position 28 of SEQ ID NO:1 (PTH₁₋₈₄), and the C-terminal amino acid residue of the PTH antagonist ends at position 84 of SEQ ID NO:1 (PTH₁₋₈₄).

28. (Previously presented) The method of claim 26, wherein the PTH antagonist is selected from th group consisting of SEQ ID NO:2 (PTH₂₋₈₄), SEQ ID NO:4 (PTH₃₋₈₄), SEQ ID NO:5 (PTH₂₈₋₈₄), and SEQ ID NO:3 (PTH₃₄₋₈₄).

29. (Previously presented) The method of claim 26, wherein the PTH antagonist is administered together with a pharmaceutical carrier or excipient.

30. (Proposed Amendment - For Discussion Only) A method for *in vivo* decreasing calcium ion concentration in blood of a subject comprising administering to a subject a PTH antagonist peptide exhibiting PTH antagonist activity, ~~which antagonist activity comprises decreasing the *in vivo* calcium ion concentration in the blood of the subject or countering hypocalcemia,~~ wherein said PTH antagonist peptide avoids stimulating adenylate cyclase activity, in [[a]] an effective, but non-toxic amount, wherein the PTH antagonist comprises a

Privileged and Confidential
FOR DISCUSSION PURPOSES ONLY - DO NOT ENTER INTO RECORD

Proposed Claim Amendments

contiguous portion of human PTH having an amino acid sequence set forth in SEQ ID NO:1 (PTH₁₋₈₄), and that has the following characteristics:

a) the N-terminal amino acid residue of the PTH antagonist starts at any position spanning from position 2 through position 34 of SEQ ID NO:1 (PTH₁₋₈₄); and

b) the C-terminal amino acid residue of the PTH antagonist ends at position 84 of SEQ ID NO:1 (PTH₁₋₈₄).

31. (Previously presented) The method of claim 30, wherein the N-terminal amino acid residue of the PTH antagonist starts at any position spanning from position 3 through position 28 of SEQ ID NO:1 (PTH₁₋₈₄), and the C-terminal amino acid residue of the PTH antagonist ends at position 84 of SEQ ID NO:1 (PTH₁₋₈₄).

32. (Previously presented) The method of claim 30, wherein the PTH antagonist is selected from the group consisting of SEQ ID NO:2 (PTH₂₋₈₄), SEQ ID NO:4 (PTH₃₋₈₄), SEQ ID NO:5 (PTH₂₈₋₈₄), and SEQ ID NO:3 (PTH₃₄₋₈₄).

33. (Previously presented) The method of claim 30, wherein the PTH antagonist is administered together with a pharmaceutical carrier or excipient.

34. **(Proposed Amendment - For Discussion Only)** A method for treating a patient having osteoporosis comprising administering to a patient having osteoporosis a PTH antagonist peptide exhibiting PTH antagonist activity, ~~which antagonist activity comprises decreasing the in vivo calcium ion concentration in the blood of the patient or countering hypercalcemia,~~ wherein said PTH antagonist peptide avoids stimulating adenylate cyclase activity, in a therapeutically effective, but non-toxic amount, wherein the PTH antagonist comprises a contiguous portion of human PTH having an amino acid sequence set forth in SEQ ID NO:1 (PTH₁₋₈₄), and that has the following characteristics:

a) the N-terminal amino acid residue of the PTH antagonist starts at any position spanning from position 2 through position 34 of SEQ ID NO:1 (PTH₁₋₈₄); and

b) the C-terminal amino acid residue of the PTH antagonist ends at position 84 of SEQ ID NO:1 (PTH₁₋₈₄).

35. (Previously presented) The method of claim 34, wherein the N-terminal amino acid residue of the PTH antagonist starts at any position spanning from position 3 through position 28 of SEQ ID NO:1 (PTH₁₋₈₄), and the C-terminal amino acid residue of the PTH antagonist ends at position 84 of SEQ ID NO:1 (PTH₁₋₈₄).

Privileged and Confidential
FOR DISCUSSION PURPOSES ONLY - DO NOT ENTER INTO RECORD

Proposed Claim Amendments

36. (Previously presented) The method of claim 34, wherein the PTH antagonist is selected from the group consisting of SEQ ID NO:2 (PTH₂₋₃₄), SEQ ID NO:4 (PTH₃₋₃₄), SEQ ID NO:5 (PTH₂₃₋₃₄), and SEQ ID NO:3 (PTH₅₄₋₃₄).

37. (Previously presented) The method of claim 34, wherein the PTH antagonist is administered together with a pharmaceutical carrier or excipient.

38. (Previously presented) The method of claim 34, wherein the PTH antagonist administration is either in a continuous or in a pulsatile manner.